Skip to content
NASDAQ · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES

NutriBand Inc. NTRB

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.0M
▼ 4.8% YoY
$-8.2M
$-5.1M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Our primary business is the development of a portfolio of transdermal pharmaceutical products. The Company’s revenues are based on providing services through our subsidiaries Pocono Pharmaceuticals operating as Active Intelligence and 4P Therapeutics. Our principal offices are located in Orlando, Florida, and our subsidiary, Pocono Pharmaceuticals, has a manufacturing facility in Cherryville, North Carolina. Our lead product under development is AVERSA™ Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with our AVERSA™ abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches.

Written from the business description in Nutriband Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 29 April 2026. Every sentence was checked against that document before publication.

Growth

USD 2.0M
Revenue, FY2025 · full 10-year series below
Revenue $M Net income $M
FY2025 · Revenue 2.0 · Net income -8.2
1M2M-5M-10M
2016201920222025
Compound annual growth
−0.7%
+16.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +16.6% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−404 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -408.4% · Net -404.1%
-500%-1000%
201620202025
ROE
FY2025 · ROE -125.6%
-1000%-2000%-3000%
201620202025
Three returns, three denominators.

Each USD of equity lost 126 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -5.1
-2M-4M
201620202025

Total assetsUSD 7.5M
EquityUSD 6.7M
CashUSD 4.6M
Current ratio6.36×

Equity funds 88% of total assets.

The 10-year record

10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
NTRB, 10-year financial record
Metric 2025202420232022202120202019201820172016
Revenue $B0.00.00.00.00.00.00.00.0◌◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌
Income tax $B◌◌◌◌◌◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0◌◌−0.0◌◌
EPS, diluted $−2.58−0.99−0.69−0.53−0.80−0.51−0.50−0.62−0.14−0.01
Dividend / sh $◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————
ROE %−125.6−162.9−73.1−43.9−65.1−80.5−211.0−263.7−3695.2—
Shares out B0.010.010.010.010.010.010.010.020.020.02

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures · 1 divergence in 48 reconciliationsAUDITED

Reconciled in 9 of the 10 fiscal years we could check. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 16 checks were skipped: the balance sheet is not tagged before 2015. 11 checks were skipped: revenue is not tagged before 2018. Nine checks were skipped: EPS is not tagged before 2016.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures1 divergent
ActivityOrthopedic, Prosthetic & Surgical Appliances & Supplies
Listed onNASDAQ
Incorporated inNevada
Fiscal year endsJanuary 31
SEC categoryemerging growth company
Data on record since2015

Share this section

Download image